CommercialCoverageMedium impact
11.17.06x, Surgical and Minimally Invasive Treatments for Urinary Outlet Obstruction due to Benign Prostatic Hyperplasia (BPH)
Independence Blue Cross·Urology·Medical Policy
Effective date
Sep 21, 2026
We identified it
Sep 22, 2026
Summary
Independence Blue Cross updated policy 11.17.06x to classify the ProVee System (permanent nitinol urethral expansion device) and CPT code 52282 as Experimental/Investigational for BPH treatment, effective 09/21/2026. This means claims for this device will not be covered. The policy continues to cover established surgical and minimally invasive treatments (TURP, laser procedures, UroLift, etc.) when medical necessity criteria are met.
Action Required
By September 21, 2026: Billing team must update claim submission protocols to deny or route for manual review any claims submitted with CPT code 52282 (ProVee System insertion) or procedure descriptions referencing the ProVee System—mark as Experimental/Investigational and not covered under Independence Blue Cross commercial plans. Update internal policy documentation and provider bulletins to reflect that ProVee is no longer a covered procedure. Ensure claim scrubbing rules in billing software flag 52282 for rejection with appropriate denial messaging referencing policy 11.17.06x. Train billing staff to inform providers that patients selecting ProVee will require out-of-pocket payment or alternative approved procedures (TURP, HoLEP, UroLift, etc.). Existing covered CPT codes (52441, 52442, 52450, 52597) and HCPCS codes (C2596, C9739, C9740) continue under prior authorization requirements per documented medical necessity criteria.